# Healthcare Podcast Weekly Digest: May 18–22, 2026

> Healthcare podcast digest for May 18–22, 2026. Eli Lilly's TRIUMPH-1 retatrutide readout, Pfizer CEO Bourla's China and monthly GLP-1 thesis, and an FDA leadership reset heading into ASCO 2026.


## Healthcare Podcast Weekly Digest

### Week of May 18 – May 22, 2026

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 1. Opening Summary

Healthcare investment debates this week were dominated by Eli Lilly's TRIUMPH-1 retatrutide Phase 3 readout (28.3% weight loss at 12 mg, 70.3 lbs), which the Street called a "clean win" but which the buy-side largely viewed as in-line, leaving the GLP-1 leadership question still open and rotation themes building. Pfizer CEO Albert Bourla delivered the week's most provocative thesis on China pharma ("half the cost and 3x the speed") and confirmed Pfizer's Medsara-derived **monthly** GLP-1 candidate, structurally differentiated from LLY/NVO weekly dosing. Meanwhile, the FDA leadership purge (Makary resignation, Diamantas as Acting Commissioner) introduced a regulatory overhang into the ASCO 2026 setup (May 30–June 3), where Revolution Medicines' pancreatic durability data is the most anticipated catalyst.

---

## 2. Key People This Week

| Speaker | Affiliation | Key Quote / Topic |
| --- | --- | --- |
| **Albert Bourla** | Chairman & CEO, Pfizer | *"It's a question of 1 or 2 years to become better than us [in early-stage discovery]"* on the China pharma threat. Also confirmed Medsara monthly GLP-1 dosing viable. |
| **Jared Holtz** | Healthcare Specialist, Mizuho | *"The execution piece of the Lilly versus Novo debate has sort of already played out"* pushed back on Bernstein's bullish LLY-vs-NVO note. |
| **Steve Grasso** | CNBC Fast Money | *"The market is sort of moving away from the GLP story… go with small cap biotech over the names that you all know"* XBI > IBB rotation call. |
| **Thomas Fuchs** | Chief AI Officer, Eli Lilly | *"Language models will never be able to be actually a good scientist"* LLY deploying 1,000-GPU NVIDIA DGX SuperPOD B300. |
| **Steve Usdin** | Washington Editor, BioCentury | *"Career staff have been hollowed out. Expect more conservative, more rigid decision-making"* on the post-Makary FDA. |
| **Stephen Hansen** | BioCentury BioPharma Intelligence | Tirzepatide *"far and away top-selling drug of all time… blasting through Keytruda and Humira"*; only ~1% obesity penetration. |
| **Louis J. Aronne, M.D.** | American Board of Obesity Medicine | *"Weight regain remains one of the biggest challenges in obesity care… these medicines can be used for long-term maintenance today."* |
| **Tom Miller** | CEO, Iambic Therapeutics | AI drug discovery 3x industry average pace; RVMD, Lundbeck, Takeda partnerships. |
| **Jake Leach** | CEO, Dexcom | G8 CGM 50% smaller, 15-day wear; FDA submission ~2027. |
| **Guy Adami** | CNBC Fast Money | *"Merck is a buy here"* on Keytruda combo strategy. |

Sources: [CNBC Fast Money, May 21, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiH69iYnQIkSXexQ8-2FH6PDSvov9OPkLXvohAxrDOOAGjm7tPAbI0ZhSnSl1ALkitXQmBpAoqjtoD9-2F8lm5X00M1jHTHexO69Al5gNDFulCxbA-3D-3DH9aT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwGmupfwGDwAJ4jHSA5usrsvsIhkmE0vZM0goyimY9u0WncK4ErA2Wz65fw8UGmXzDHAWVEeRR-2FBHXzh0KmNPEqPAEM5t3wW2rs-2Bo1-2FfFV0Nr-2FJV1vjKFGWT6GCgpRKiGaA-3D-3D); [In Good Company with Nicolai Tangen, May 20, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjJEmJg7wHqJDkRsCs89mBmAxZuRok3V14wIA4pYnzc31DSPme1bqIgNE-2BI76Q2XfL60cpH41mT9VSf37WTlLkvg-3D-3DZx7U_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwOdBPpjuTr2-2BF0EyzN7pNwEz2wcEMnQ7gPIbOTkn0nhZBNJICf272RRHLwSl-2FQ3OFqKprxiamA90X0Xi2i-2BKw3yo8d0BCcuUJjVv7RY5V0Q8bZGXumvmwO1HiMCdvHq7gw-3D-3D); [BioCentury This Week, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgHsTdGB6mJ7LtlD410WJ99-2BD4GYT51BJfiCHLu62W-2F0l4PYwyCwAW3n4nf-2FLCZbRSKd-2BIEEgCuMI-2BBgzE6vYNI7g3gcBw9iR-2Bsz1KNGnyhhA-3D-3DP_qb_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwKPzGksWoHeH9gZFn10XAd7rc6pXxSu1wR8VTeoXSks78a89O1vNUpt9aj4pIrUjqB0CjjXWm-2Ft-2FcN6U4fvdY4IflHz5Q6W4lt2IHfzCc7XSThUHSb4ZudKCXMjWmYfkRg-3D-3D); [The AI in Business Podcast, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgeS8gAOkODa1oxrHH8n54Rm-2BHOD2ixrgg9ercAFspEs0BfTDttdW5IilEIriJKhO58hAIYT8H1JEjcFmJgne94u7L3y77q-2BhVexTJV33MZTQ-3D-3DJRo9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwH1HKEyzDIrTHKmrIsGCqe0qoZ8Pnkj82BIbL6M1fDKeisGp5lDbl9OysdRbDp2aIgATHmCuzgedXHEDMu-2BK4jQlQmruHZOXCWF-2ByHWlZPzmPEY-2FxVG-2BCjASAxYJaX-2BI5Q-3D-3D); [Diabetes Connections](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOifDE4mhK6xjIA0KpRoS4Qrf977ZpDGDFpY-2FjhHZPLkoyGQjcVg-2FOE3cfUWxtY0Sl7GfbE29kPUcEMPfBFW8L9lHb2u8k2kfg7xDSREnQWxtA-3D-3Dy-d-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwH1HKEyzDIrTHKmrIsGCqe0qoZ8Pnkj82BIbL6M1fDKeisGp5lDbl9OysdRbDp2aIgATHmCuzgedXHEDMu-2BK4jQlQmruHZOXCWF-2ByHWlZPzmPEY-2FxVG-2BCjASAxYJaX-2BI5Q-3D-3D).

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 3. Hot Topics

### Eli Lilly (LLY): TRIUMPH-1 Retatrutide Readout

The week's most-discussed clinical event. TRIUMPH-1 Phase 3 (announced May 21):

- **12 mg dose**: 70.3 lbs / 28.3% body weight loss at 80 weeks; **65.3% of patients achieved BMI <30**, with 37.5% of class 3 obesity patients moving below the obesity threshold.
- **104-week extension** (BMI ≥35): **average 85.0 lbs / 30.3% weight loss** at top dose.
- **9 mg / 4 mg**: 64.4 lbs (25.9%) and 47.2 lbs (19%), respectively.
- Cardiovascular markers: improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic BP, hs-CRP.
- Discontinuation due to AEs: 4.1% / 6.9% / 11.3% at 4/9/12 mg vs. 4.9% placebo.

Sell-side: RBC called it a *"clean win"* with a *"clean safety profile, combined with best-in-class efficacy across all doses"* modeling 2030 sales of $4.9B / 2034 sales of $11.0B at 70% PoS. Wolfe ($1,350 PT) said retatrutide *"sets a new bar for next-generation therapies to differentiate."* Truist (Buy, $1,281) and Jefferies ($1,330 from $1,300) joined the upgrades.

Buy-side counter: Mizuho's Jared Holtz: *"We were all sort of expecting 25 to 30% weight loss for this drug... So I wasn't shocked by the results"* and pointedly noted LLY was **down 3% YTD** that session vs. MRK/JNJ/BMY each up ~10%. LLY closed +1.96% at $1,038.83 on the news.

### Pfizer (PFE): CEO Bourla's "In Good Company" Interview

Bourla on **In Good Company with Nicolai Tangen** (May 20, 2026) was a tour de force on Pfizer's positioning and the sector:

- **Post-COVID recovery**: *"2024 and 2025 were exceptional years in terms of performance. Everybody was very impressed how we are able to grow top line and beat analysts and reduce cost"* overcame collapse from $56B COVID revenue (2022) to ~$6B run-rate.
- **R&D claims**: Phase 2 success rate 50%+ (vs. industry 25-30%); overall clinical success rate 18-19% (~2x industry).
- **Medsara / monthly GLP-1**: After two internal obesity assets failed (liver tox), PFE outbid Novo Nordisk. *"We can debate, is it going to be better than Lilly's, worse than Lilly's? But it's going to be monthly. Lilly's and Novo's will be weekly. That we know now with a very high level of confidence."* On obesity overall: *"Not at all [changed view]. I think I'm more and more optimistic."*
- **Drug pricing overhang**: *"[The debate] drove 2025 to be the lowest multiple in the history of the industry and the lowest available fund for biotech."*

Pfizer also (May 20) advanced its **25-valent pneumococcal vaccine candidate (25vPnC)** into pivotal Phase 3 pediatric trials, citing 9-15x higher immunogenicity vs. Prevnar 20 for serotype 3.

### Merck (MRK)

MRK +3% on May 21 on **Phase 3 data showing Keytruda + a targeted cancer drug reduced lung cancer progression/death by 65% vs. Keytruda alone** as first-line therapy. Guy Adami: *"When you start to use Keytruda with other drugs, that might extend it or give them sort of a new lease on life, so I think Merck is a buy here."* Read-through: a *"small negative for Summit Therapeutics"* (PD-1/VEGF). Separately, Merck dosed first patient in Phase 3 PROCEADE-CRC-03 (anti-CEACAM5 ADC in metastatic colorectal).

### UnitedHealth (UNH)

- **Mizuho raised PT to $440 from $410** (May 20), Outperform, citing *"reduced likelihood of negative medical loss ratio shifts through the end of 2026."*
- **BofA raised PT to $420 from $380** (May 13), Neutral, post-conference tone was *"bullish,"* with management confident on returning to the low end of target margins in most businesses by 2028.
- **Berkshire Hathaway exited its UNH position** (Q1 2026 13F, disclosed May 15) alongside V, MA, DPZ, AON exits.
- **Membership reset**: UNH deliberately shed ~1.3M MA lives for 2026, which The Motley Fool (May 13) noted improved Q1 MCR from 88.9% to 83.9%.
- Stock at $385.14 (May 18), down 2.21% on Mangione murder-trial evidentiary ruling.
- FactSet consensus: avg rating overweight; mean PT $391.16.

### Novo Nordisk (NVO)

Down ~13% in the May 21 session. Mizuho's Holtz called the >1M-patient oral Wegovy franchise *"completely overlooked"*: *"Novo is gaining a lot of momentum in the oral market… [bullishness on Lilly oral] negates a lot of the success that Novo has had early on with the Wegovy pill."* NVO is reportedly preparing an aggressive **global rollout of oral Wegovy outside the U.S.** (UK, Germany), per May 18 CNBC reporting, and recently launched multi-month subscription plans for Wegovy in the U.S. to stabilize out-of-pocket costs.

### Revolution Medicines (RVMD)

Up **93%** recently; **#1 holding in XBI ETF**. Mizuho's Holtz, on the most anticipated ASCO readout: *"The one that the street's really looking forward to the most… is Revolution. Pancreatic [cancer] has really taken center stage… we'll get probably a little bit more durability or duration data out of Revolution at this meeting."*

### Dexcom (DXCM)

CEO Jake Leach detailed the **G8 CGM**: 50% smaller; **15-day wear baseline** for all future sensors; new silicon chip + adaptive algorithm. Launches glucose-only, with multi-analyte (ketones + potassium) to follow. **FDA submission ~2027; OUS launch ~2028.**

Sources: [Eli Lilly TRIUMPH-1 release, May 21, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiH69iYnQIkSXexQ8-2FH6PDSvov9OPkLXvohAxrDOOAGjm7tPAbI0ZhSnSl1ALkitXQmBpAoqjtoD9-2F8lm5X00M1jHTHexO69Al5gNDFulCxbA-3D-3DRw58_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwBDIYxBgfe9n3Ia8RQIyZkSAXALoyhVdJWaY2i-2BNvxvsghSkDIgtPxG3cy6ETgFJlIIuuOXCvLA1L0AGmY0c8bdjCtaQnZOJWWlUPXyBZ40fcMOol5S71-2FJcRXngFQ14-2BQ-3D-3D), [In Good Company, May 20, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjJEmJg7wHqJDkRsCs89mBmAxZuRok3V14wIA4pYnzc31DSPme1bqIgNE-2BI76Q2XfL60cpH41mT9VSf37WTlLkvg-3D-3DzOi-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwAkAAevIQur1fqH1Mg657JR9lCMUGIvibuxduVWQSgaOlLlbYwDGR5tvGBs0rxPkg2WmOVjP7FGQ3ZkYsp3gv6hUvmBtO-2B9qd7L3t5-2FVjGJ5eycz0kTAW-2BTU3Appu7SE7g-3D-3D).

---

## 4. Key Debates (Bull vs. Bear)

### Debate 1: LLY vs. NVO, Is the Race Already Decided?

**Bull LLY (Bernstein, RBC, Wolfe, Truist, Jefferies)**: TRIUMPH-1 is *"a new benchmark for anti-obesity medications"* (Truist) and *"strengthens GLP-1 franchise leadership and differentiation"* (Wolfe). Lilly will "cream" Novo, including in oral.

**Bear / Contrarian (Holtz, Mizuho)**: *"The execution piece of the Lilly versus Novo debate has sort of already played out."* Retatrutide data was in-line, not blow-out; NVO's >1M-patient oral Wegovy franchise is *"being completely overlooked, again, in my opinion, versus what Lilly's doing."*

**Wild Card (Bourla, PFE)**: Both miss the monthly dosing angle; PFE/Medsara confirmed monthly is feasible.

### Debate 2: China Pharma, 2-Year Threat or Decade-Plus?

**Aggressive timeline (Bourla)**: Chinese pharma operates at *"half the cost and 3x the speed."* *"It's a question of 1 or 2 years to become better than us [in early-stage drug discovery]."* Pfizer signed a licensing deal with **3S Bio**. Parallel: *"What they did with EVs, with solar panels, with batteries, they will do with medicines."* Nature Index 2025: **8 of top 10 research universities by scientific output are Chinese** (only Harvard remains US in top 10).

**More measured (Tom Miller, Iambic)**: Frames it as *"a rising tide of innovation,"* not zero-sum.

### Debate 3: GLP-1 Tolerability, Structural Bear or Solvable?

**Bear (Stephen Hansen, BioCentury)**: *"These are drugs that are not well tolerated at the moment… you've got patients coming on and going off therapy."*

**Bull resolution**: Dual/triple combo improvements (e.g., retatrutide); LLY SURMOUNT-MAINTAIN / ATTAIN-MAINTAIN data confirmed that lower-dose maintenance preserves nearly all prior weight loss (within 0.9 kg switching Wegovy MTD to Foundayo; within 5.6 kg on reduced 5 mg Zepbound).

### Debate 4: Sector Rotation, Stay in GLP-1 or Move to Oncology?

**Rotate to small-cap biotech (Steve Grasso)**: *"The market is sort of moving away from the GLP story... go with small cap biotech."* XBI **outperforming IBB** by a large margin; RVMD #1 holding up 93%.

**Stay large-cap (Grasso/Adami)**: MRK/JNJ/BMY each up ~10% on combination patent-cliff strategies.

### Debate 5: FDA Outlook

**Bear (Steve Usdin, BioCentury)**: *"The White House doesn't want drama from FDA right now. It wants quiet competence... career staff are going to be making decisions. But they've been hollowed out. The most forward-looking staff have been fired or left. So I think you can expect more conservative decision-making, more rigidity."*

**Mitigation**: Greg Davis (FDA veteran) returned to CDER for institutional continuity.

Sources: [CNBC Fast Money, May 21, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiH69iYnQIkSXexQ8-2FH6PDSvov9OPkLXvohAxrDOOAGjm7tPAbI0ZhSnSl1ALkitXQmBpAoqjtoD9-2F8lm5X00M1jHTHexO69Al5gNDFulCxbA-3D-3D_H9U_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwNGCKQDF1XEd4ShWWOcfXlgNiow1pOqSuYfuKLPJ4D9wMoldXozoDuanny14SmtnkKtTdHpNtfoXZewzA0eRfz7NvazzrgUVEW-2BHB5Ik1XutI5428nGvLHn3qN8rsaqGIw-3D-3D); [In Good Company, May 20, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjJEmJg7wHqJDkRsCs89mBmAxZuRok3V14wIA4pYnzc31DSPme1bqIgNE-2BI76Q2XfL60cpH41mT9VSf37WTlLkvg-3D-3DQeG-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwE2Ffa6TM8I1AxJMCQLlXdiN8aAPDoomhc6JTrnlLekzJ-2BP18d15r-2B4ktIvDe88jVqj066QFQTA-2F-2FIeL9D5TFbd0-2BbkR6-2B8M9J-2Fm06n0EGrQPY2FPP8YYNjGubJg6w2pVg-3D-3D); [BioCentury This Week, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgHsTdGB6mJ7LtlD410WJ99-2BD4GYT51BJfiCHLu62W-2F0l4PYwyCwAW3n4nf-2FLCZbRSKd-2BIEEgCuMI-2BBgzE6vYNI7g3gcBw9iR-2Bsz1KNGnyhhA-3D-3DGZ4j_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwFeq96Hd0Kckr-2F6X-2Bcz0uut-2Bjd-2Bi-2FZn-2B5QdwrlxT530aYyk3p2HsyijqaGLzzxvIVqg6-2FAnXhFjZTDtJxzdyXG-2FgAPle3DkQJYQkS9yijZkLFj9jyr4Hd8ExKYKMuntkYA-3D-3D).

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 5. Emerging Themes

1. **Monthly GLP-1 dosing as PFE's structural differentiator.** Bourla's confirmation that Medsara Phase 2 supports monthly cadence reframes the obesity competitive set from a two-horse race into a three-way structural debate. Watch how the Street treats this once PFE shares Phase 3 plans.

2. **AI infrastructure as a pharma moat.** Lilly's **1,000-GPU NVIDIA DGX SuperPOD B300** is the most powerful supercomputer in pharma. Thomas Fuchs frames it as a *"scientific instrument"* and is skeptical of LLMs in discovery, using diffusion/generative flow models instead. Bourla says AI + biology delivers *"very different level of standards of care"* by ~2030.

3. **DAC (Degrader-Antibody Conjugate) modality rebooting.** Genmab/Colgen (March 2026), Roche/C4 (April 2026), and MRK/C4 (Dec 2023 reference) anchor a wave of deals. Field constrained: only **one DAC in clinical trials** (CD33-targeted, GSPT1 payload); *"zero diversity on the degrader part so far."* Orem's ORM-5029 fatality is a reminder of liver-tox tail risk.

4. **GLP-1 indication expansion beyond obesity.** T1D 4,088-patient cohort: hypoglycemia HR=0.72 (p=0.021), no DKA increase, lower all-cause mortality. JAMA Network Open >840k-patient study: lower breast-cancer mortality and recurrence over 10 years.

5. **Pharmacy services consolidation accelerating.** May 21 VMG Health: PE and strategic buyers acquiring specialty pharmacies, infusion services, compounding platforms, the "files and stores" strategy typified by CVS/Rite Aid. Home health/hospice multiples stabilizing at 10–15x EBITDA with tighter underwriting.

6. **Biotech IPO window is open.** Q2 2026: Kylero +32% from IPO; Alamar +27%; Veridermix (Q1 IPO, male pattern baldness Phase 3) up ~+500% within lockup. Hansen: *"pretty good"* despite *"upheaval and uncertainty."*

---

## 6. Deals & M&A Tracker

| Deal | Date | Terms / Notes |
| --- | --- | --- |
| **Pfizer ← Medsara** | Recent | Monthly GLP-1; PFE outbid Novo Nordisk |
| **Pfizer ← 3S Bio** | Recent | Chinese biotech licensing, strategic access to China innovation |
| **Roche + C4 Therapeutics** | Apr 2026 | DAC collaboration |
| **Genmab ← Colgen** | Closed Mar 2026 | DAC/targeted protein degradation platform |
| **Eli Lilly ← Engage Biologics** | May 20, 2026 | **Up to $202M cash** (upfront + milestones); Tethosome non-viral DNA delivery platform |
| **Eli Lilly + UNICEF USA** | May 14, 2026 | $50M commitment; 150th anniversary; pediatric NCDs across 21 LMICs |
| **AbbVie ← Capstan Therapeutics** | (2025 ref.) | Cell and gene therapy pipeline (cited in defensive positioning analysis) |
| **CVS ← Rite Aid (files + stores)** | Recent | Targeted rx-file/retail location pickup; "files and stores" model |

Sources: [Eli Lilly press release / The Fly, May 20, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjJEmJg7wHqJDkRsCs89mBmAxZuRok3V14wIA4pYnzc31DSPme1bqIgNE-2BI76Q2XfL60cpH41mT9VSf37WTlLkvg-3D-3Dnf8Q_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwM5fh-2FvBle8SOUp0wrF76-2ForbFfZpo7sLJ3m7y6M1cNv7EaArpCFOUbiLENeb85-2B7uj-2FRTxs8A762SLdd3-2FUCh3H-2BUhPzNSckPxveLnCkZyMot8TIWFgRJDtDnpjYyua-2BQ-3D-3D); [BioCentury This Week, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgHsTdGB6mJ7LtlD410WJ99-2BD4GYT51BJfiCHLu62W-2F0l4PYwyCwAW3n4nf-2FLCZbRSKd-2BIEEgCuMI-2BBgzE6vYNI7g3gcBw9iR-2Bsz1KNGnyhhA-3D-3DX9jO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwJ5oHTuYrfQXMcE92-2F0Ubuh-2BNfpgG6w3qAd9nzjIZss9TXruNekpH5ZG8lmCu3ehMVKFocCEiM44XqzYctWPHhDexM7cyRU73QzKGlxYLxdW-2FM16ZGcpzL0p4pc1Qht21g-3D-3D).

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## 7. Regulatory Watch

**FDA Leadership Reset (week's biggest sector overhang):**

- **Dr. Marty Makary resigned** as FDA Commissioner (May 12), reportedly over the administration's authorization of fruit-flavored e-cigarettes. Per Steve Usdin (BioCentury), *"putting euphemisms aside, he was fired."*
- **Kyle Diamantas** (FDA's top food regulator) named Acting Commissioner.
- Multiple senior departures: **Tracy Beth Hoeg out as Acting CDER Director → Greg Davis in**; Catherine Charama out; Jim Traffikant (Chief of Staff) out → Lowell Zeta in; Jeremy Walsh (Chief AI Officer) out, TBD replacement.
- Usdin: Richard Pastor *"very unlikely"*; White House wants someone *"pliable… listening to Dave Riggs from Lilly and Albert Borla from Pfizer, not biotech CEOs."* Next Commissioner likely from small/mid-cap biotech.
- Senator Bill Cassidy (HELP Chair) described as *"Cassidy Unchained"*: *"no mood to do the administration any favors."*

**FDA Approval / PDUFA Activity:**

- **Levacetylleucine (IntraBio, AQNEURSA)** for ataxia-telangiectasia, Priority Review; **PDUFA: Sept 19, 2026**.
- **Pembrolizumab (MRK)**: accelerated + regular approval summary for HER2-positive gastric cancer (May 15, AACR journal); Project FrontRunner front-line push.
- **Sonrotoclax**: next-gen BCL2 inhibitor approved early May for relapsed mantle cell lymphoma.
- **TWINRIX (GSK)** combination hepatitis vaccine: updated approval letter (May 16).
- **Eli Lilly appeal denied by Supreme Court** (May 18) in Eli Lilly v. Streck, Medicaid award ruling stands.

**Policy / Tariffs:**

- **Section 232 100% ad valorem tariff** on imported patented pharmaceuticals and APIs, rolling out July/September 2026, but heavily blunted: generics, biosimilars, and EU/UK imports broadly exempt; companies onshoring + accepting "most favored nation" pricing get functional exemptions. Effectively a negotiating tool tied to **$400B in manufacturing commitments**.
- **Trump expanded TrumpRx.gov** (May 19) with additional offerings.
- **CMS finalized a 2.48% net rate increase for 2027 Medicare Advantage plans** (S&P Global, May 21), below domestic healthcare cost inflation, sustaining MA margin pressure.

---

## 8. Week Ahead

| Catalyst | Date | Companies |
| --- | --- | --- |
| **ASCO 2026 Annual Meeting (Chicago)** | **May 29 – June 2, 2026** | **RVMD** (pancreatic durability, most anticipated), **MRK** (Keytruda combos), **BNTX** (bispecific antibody + chemo), **Roche**, **Summit** (PD-1/VEGF final read), **JNJ** (TALVEY/MonumenTAL-3 ahead of EHA), small-cap ADCs (Corpus/Bicara) |
| **FDA PDUFA: CTx-1301 (Cingulate)** | May 31, 2026 | Cingulate Therapeutics, once-daily ADHD formulation |
| **EHA 2026 Congress** | Mid-June 2026 | JNJ Phase 3 MonumenTAL-3 (TALVEY in multiple myeloma) |
| **BAT2506 (Bio-Thera), golimumab biosimilar** | Near-term | FDA action |
| **PDUFA: AQNEURSA (IntraBio)** | September 19, 2026 | First specific therapy for ataxia-telangiectasia |
| **PFE Medsara monthly GLP-1 Phase 3** | TBD | Pfizer |
| **Dexcom G8 FDA submission** | ~2027 | DXCM |
| **New FDA Commissioner confirmation** | *"Very long time"* (Usdin) | Sector-wide |

Sources: [BioCentury This Week, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgHsTdGB6mJ7LtlD410WJ99-2BD4GYT51BJfiCHLu62W-2F0l4PYwyCwAW3n4nf-2FLCZbRSKd-2BIEEgCuMI-2BBgzE6vYNI7g3gcBw9iR-2Bsz1KNGnyhhA-3D-3DjdiZ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwJ2sEoCVVY6sGTV-2BziJMLhiX-2FCSVWp1ZwaLPQExD1U-2Br-2BudjYZtWc47laZKM2H-2FZGuXM1z5n5FfjnLzTv3QTwcGvstdhF-2FJvE6dLiMBJ-2Bdq9Iop2EemxlsYA3D8z5KHikg-3D-3D); [CNBC Fast Money, May 21, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiH69iYnQIkSXexQ8-2FH6PDSvov9OPkLXvohAxrDOOAGjm7tPAbI0ZhSnSl1ALkitXQmBpAoqjtoD9-2F8lm5X00M1jHTHexO69Al5gNDFulCxbA-3D-3DMCxm_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwG2M3HgxLXYXswLRU5-2F3C9P5kwaDjxGhbBvaTJsBjFRoZdIlHeRejMDg-2FclvHgzLteDep3HH3lmhAJXzRtY-2F74-2B30Ep8Rb8BYMjHlHeK7xtzKDx3i-2FJ4MQZx4CQ-2Bj4Xqng-3D-3D); [Diabetes Connections](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOifDE4mhK6xjIA0KpRoS4Qrf977ZpDGDFpY-2FjhHZPLkoyGQjcVg-2FOE3cfUWxtY0Sl7GfbE29kPUcEMPfBFW8L9lHb2u8k2kfg7xDSREnQWxtA-3D-3DmitB_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwD3u9P04Fo-2B8c54TSais9lAxsuxzc-2Fp5P0CfWwsKz-2FmDgZ0-2B-2Fn-2B2pSgFYfXYCiXKGMEH85kg-2BiQywpWJI1d-2FZkS7KBPb98UOYzWtxPDS6MKSJU4MJ3x7F9Dskr8fvKGBgw-3D-3D).

---

## Sources

1. [CNBC Fast Money, May 21, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiH69iYnQIkSXexQ8-2FH6PDSvov9OPkLXvohAxrDOOAGjm7tPAbI0ZhSnSl1ALkitXQmBpAoqjtoD9-2F8lm5X00M1jHTHexO69Al5gNDFulCxbA-3D-3D0mYN_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwCDlxlIg-2FhRdcjO7-2BQc5tNNRK8Zfo2eZgTZM-2B89z7ZJSE1l7tEKL07OBSpm1-2BLg9avQpFT5B-2BlTdnjoVsk9Mj1CABdsFSt4Bp9FlNA1xVt5YByGG7JQ-2FGKy0FtAdasGkbg-3D-3D)
2. [In Good Company with Nicolai Tangen (Albert Bourla, Pfizer CEO), May 20, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh1YJHmfaeqnmvFF7MKRzYjJEmJg7wHqJDkRsCs89mBmAxZuRok3V14wIA4pYnzc31DSPme1bqIgNE-2BI76Q2XfL60cpH41mT9VSf37WTlLkvg-3D-3D2xFp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwDjcolXeSzPq3653i-2FrGQ5xIN7iEWExyltENHtt6IEwlrulLeugAbAAKa-2FO1cAxAeOvBaZZVC88misgx5tx0mWx-2BBBcFlK-2BcRZAxyTDSgquwnn8PKG1Q-2FXR-2FjxuKJeOCfA-3D-3D)
3. [BioCentury This Week, Ep. 367, May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgHsTdGB6mJ7LtlD410WJ99-2BD4GYT51BJfiCHLu62W-2F0l4PYwyCwAW3n4nf-2FLCZbRSKd-2BIEEgCuMI-2BBgzE6vYNI7g3gcBw9iR-2Bsz1KNGnyhhA-3D-3D_Zeh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwLUXmWgEkqShMaXPie-2BI8-2Bts1vptqVkCGxXAb6cPdcVWwPxnnAjQV6FLDMp94t8gFMVgAjLZkK809XIAOux-2BaH2wVThjHDySm0fJzVwM4y7lrH9ORWn4QvMkvQGszWtmcQ-3D-3D)
4. [The AI in Business Podcast (Thomas Fuchs, Lilly Chief AI Officer), May 19, 2026](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgeS8gAOkODa1oxrHH8n54Rm-2BHOD2ixrgg9ercAFspEs0BfTDttdW5IilEIriJKhO58hAIYT8H1JEjcFmJgne94u7L3y77q-2BhVexTJV33MZTQ-3D-3D__Wy_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwKQoB-2FlTUnZ-2Bb9zKQYbd42K2L6WmT474u8GRVaFiVj6H9Qel3Hw937wDZOS-2BuKFjzwGvQ4k4flbq8gqFT05fyaYxcP-2BRvszKYaJ5Rb-2FBku5CRhGpMPaJLb0cnik9f6nJAw-3D-3D)
5. [Diabetes Connections (Jake Leach, Dexcom)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOifDE4mhK6xjIA0KpRoS4Qrf977ZpDGDFpY-2FjhHZPLkoyGQjcVg-2FOE3cfUWxtY0Sl7GfbE29kPUcEMPfBFW8L9lHb2u8k2kfg7xDSREnQWxtA-3D-3D1-nD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUl-2BKS-2FhFQsg6j532owskyjzQeIt5vN-2BgSiml9WAIlnwErzXE5dWvNaNc8gvNd2RqjCevHwZI5gxiIFTMieKu9TwA1ts5rw7bUmeWen4ud1YYFAFHIvbEJqep4i02a-2FAwzH5AtHpGXttbi5LEGN-2BqTXpd38Cd-2FV4sqyAzWMruuxug-3D-3D)

**Coverage gaps this week**: No material podcast discussion of HUM, ELV, CI, CVS, HCA, ISRG, VRTX, REGN, GILD, ABBV, AMGN. No tariff-specific podcast commentary (tariff coverage drawn from web/news sources only). Medicare Advantage CMS rate context is from S&P Global, not from podcast/transcript material.

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```